Last reviewed 2026-05-13 · How we verify

VK2735

VK2735 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon signaling pathways to promote weight loss and improve metabolic parameters.

VK2735 is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon signaling pathways to promote weight loss and improve metabolic parameters. Used for Obesity or overweight with weight-related comorbidities, Type 2 diabetes mellitus.

At a glance

Mechanism of action

By simultaneously activating GLP-1 and glucagon receptors, VK2735 enhances insulin secretion, reduces appetite, increases energy expenditure, and promotes lipolysis. This dual mechanism is designed to produce greater weight loss and metabolic benefits compared to GLP-1 monotherapy, with potential advantages in glycemic control and cardiovascular outcomes.

Approved indications

• Obesity or overweight with weight-related comorbidities
• Type 2 diabetes mellitus

Common side effects

• Nausea
• Vomiting
• Diarrhea
• Gastrointestinal disorders

Key clinical trials

• VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) (PHASE3)
• VK2735 for Weight Management Phase 3 (PHASE3)
• VK2735 for Weight Management Phase 2 (Venture Oral Dosing) (PHASE2)
• Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 (PHASE1)
• VK2735 for Weight Management Phase 2 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VK2735 CI brief — competitive landscape report
• VK2735 updates RSS · CI watch RSS
• Viking Therapeutics, Inc. portfolio CI